Published • loading... • Updated
New study reveals promising new way to find serious liver disease earlier
The LiveWell study found the Cumulative Liver Damage Index outperformed standard first-line tests and could send high-risk patients straight to scans.
- Predictive Health Intelligence announced a new method using existing NHS blood test data to identify serious liver disease earlier, with findings from the LiveWell study presented this week at a major European liver congress.
- Liver disease remains silent for many years, leaving many people unaware until advanced damage occurs, despite being one of the UK's fastest-growing causes of death with mortality increasing more than fourfold since the 1970s.
- The LiveWell study of 994 participants found CLDI significantly more effective than standard first-line liver investigations at identifying clinically significant disease, while existing methods researchers note are often expensive and difficult to scale.
- Charlotte Guzzo, chief operating officer of Sano Genetics, said CLDI's accuracy using existing NHS data "changes what earlier identification can realistically look like at scale," while high-risk patients could be referred directly for liver scans instead of multiple testing rounds.
- HepatoSIGHT is expanding across South West of England with further NHS rollout planned in 2027, while an 8,000-patient follow-up study across multiple sites is underway with results expected later this summer.
Insights by Ground AI
58 Articles
58 Articles
Coverage Details
Total News Sources58
Leaning Left1Leaning Right1Center43Last UpdatedBias Distribution96% Center
Bias Distribution
- 96% of the sources are Center
96% Center
C 96%
Factuality
To view factuality data please Upgrade to Premium
